This inventor holds 27 USPTO granted patents and 3 published patent applications, plus 7 CIPO patents and 8 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Theraclone Sciences, Inc., International Aids Vaccine Initiative, Scripps Research Institute. Active years: 2005-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Mayne Island, CA (2008)
- Oakland, CA (US) (2005 - 2012)
- Bellevue, WA (US) (2013 - 2024)
Company Filing History:
16 out of 28 
14 out of 72 
14 out of 1,208 
Years Active: 2005-2025
Areas of Expertise:
Title: **Po-Ying Chan-Hui: Innovator in HIV Research Based in Bellevue, WA**
Introduction
Po-Ying Chan-Hui is a prominent inventor located in Bellevue, Washington, known for his groundbreaking work in the field of HIV research. With a remarkable portfolio of 25 patents, Chan-Hui has made significant strides in developing monoclonal antibodies with broad and potent neutralizing activity against HIV-1.
Latest Patents
Among Chan-Hui's latest patents is an innovative method for obtaining broadly neutralizing antibodies (bNabs) focused on trimeric forms of the HIV-1 envelope glycoprotein. This invention encompasses a comprehensive screening process of memory B cell cultures from donor PBMC samples to identify those that demonstrate neutralization activity against various HIV-1 species. The method enables the cloning of a memory B cell with significant broad neutralization capabilities, leading to the rescue of monoclonal antibodies. These antibodies possess the ability to bind selectively to epitopes from the Env proteins in their native or monomeric states and inhibit infections from multiple HIV-1 clades. The consequent compositions of human monoclonal anti-HIV antibodies are provided for use in prophylactics, diagnostics, and treatment of HIV infections. Additionally, Chan-Hui's patents include methods for generating these antibodies through immunization using epitopes sourced from conserved regions within the variable loops of gp120, as well as immunogens for anti-HIV1 bNAbs and vaccination strategies utilizing suitable epitopes.
Career Highlights
Throughout his career, Po-Ying Chan-Hui has contributed significantly to biomedical research, particularly in HIV treatment and prevention. He has collaborated with notable companies, including Theraclone Sciences, Inc. and The Scripps Research Institute, where he honed his skills and expanded his knowledge in antibody development and immunotherapy.
Collaborations
Chan-Hui has worked alongside esteemed colleagues such as Steven Frey and Ole Olsen. Their teamwork has fostered advancements in the understanding and treatment of HIV, further solidifying Chan-Hui's reputation as an innovator in the medical research community.
Conclusion
With a strong foundation in immunology and a focus on developing therapies for HIV, Po-Ying Chan-Hui exemplifies the impact inventors can have on global health challenges. His patents underscore a commitment to tackling critical health issues through innovative research and collaboration. As he continues to push the boundaries of scientific discovery, his work holds immense potential for improving the lives of those affected by HIV.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile